Shaperon Past Earnings Performance
Past criteria checks 0/6
Shaperon's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 89.2% per year.
Key information
-16.2%
Earnings growth rate
-1.6%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -89.2% |
| Return on equity | -65.3% |
| Net Margin | -5,762.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Shaperon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 215 | -12,403 | 5,194 | 7,462 |
| 30 Sep 23 | 142 | -11,548 | 4,280 | 7,575 |
| 31 Dec 22 | 2,000 | -10,673 | 4,726 | 7,765 |
Quality Earnings: A378800 is currently unprofitable.
Growing Profit Margin: A378800 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A378800's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A378800's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A378800 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A378800 has a negative Return on Equity (-65.29%), as it is currently unprofitable.